Moleculin Biotech issued a letter to shareholders updating its FDA designation of an orphan drug and the IND status for Annamycin.
Nutra Pharma revealed a collaboration with International Security Group to develop a nerve agent countermeasures.
Nature’s Sunshine leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Immunogen, AVEO Pharmaceuticals and Alnylam Pharmaceuticals.
By Mike Rodger
Valens GroWorks (CSE:VGW)(CSE:VGW.CN) (the “Company” or “Valens”) is pleased to announce Valens Agritech Ltd. (“VAL”), a wholly owned subsidiary of the Company, has received a Dealer’s Licence pursuant to the provisions of the Controlled Drugs and Substances Act and its Regulations and will now begin operations. The issuance of the
DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on developing new cancer therapies, today announced the formalization of an agreement with PRA Health Sciences (Nasdaq: PRAH), a leading contract research organization (CRO) to conduct the Company’s Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
InMed Pharmaceuticals has filed to apply for a provisional patent in the US related to INM-085 as a cannabinoid-based topical therapy for glaucoma.
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces plans for research and formulation development (“R&D”) on nonsteroidal anti-inflammatory drugs (“NSAIDs”) utilizing its patented technology and as provisioned within its previously announced 2017 & 2018 R&D program.
Oncolytics Biotech announced the US Food and Drug Administration granted a fast track designation for Reolysin, an immuno-oncology viral agent treating metastatic breast cancer.
By Pia Rivera
Valens GroWorks Corp. (CSE:VGW)(CSE:VGW.CN)(CNSX:VGW) (the “Company” or “Valens”) is pleased to announce the appointment of A.Tyler Robson, currently Chief Operating Officer and a Company director, as its new Chief Executive Officer (“CEO”) effective immediately. Rob van Santen, CEO of Valens GroWorks Corp., will remain engaged as Chief Financial Officer (“CFO”)